Hepatocellular carcinoma remains a leading cause of cancer-related deaths worldwide, with chronic hepatitis C virus (HCV) infection driving both its development and progression. However, the role of HCV eradication in patients already diagnosed with advanced hepatocellular carcinoma has been less clear, particularly when systemic therapies such as immune checkpoint inhibitors are used. Concurrent therapy for Hepatocellular CarcinomaA recent study explored the impact of HCV eradication in patients with unresectable or advanced hepatocellular carcinoma treated with the immunotherapy combination of atezolizumab and bevacizumab (AtezoBev). Biological Rationale and Clinical ImpactThe biological explanation lies in how HCV eradication reshapes the tumour microenvironment. This synergistic effect suggests that combining DAA therapy with immunotherapy could represent an optimal approach for patients with advanced hepatocellular carcinoma.